In this episode of the Business of HLTH Podcast, we explore one of the most urgent challenges in modern medicine and a breakthrough that could fundamentally change how we detect it.

Natalie sits down with Mike Banville, CEO and President of ALZpath, a company at the forefront of transforming Alzheimer’s diagnostics through its proprietary pTau217 antibody. With the potential to enable simple, scalable blood tests that detect disease years before symptoms appear, this innovation could shift Alzheimer’s care from late-stage reaction to early intervention.

Mike shares how ALZpath is navigating the complex path from scientific discovery to real-world clinical adoption, working alongside global diagnostic leaders to bring this technology to patients worldwide. The conversation also dives into what it takes to scale in a highly regulated, partnership-driven ecosystem and why focus, adaptability, and execution matter at every stage.

If you’re interested in the future of diagnostics, the evolution of Alzheimer’s care, or how breakthrough science becomes accessible at scale, this is a conversation worth listening to.